$9.06
+0.67%Price chart
Sep 16Sep 21Sep 24Sep 29Oct 2Oct 7Oct 14Oct 19
Key dataOct 19, 2026
Open$9.45
From 52W high−69.79%
Volume2.00
Market cap$1.04B
P/E (TTM)—
P/S (TTM)145.5x
Div yield—
Key dataOct 19, 2026
Open
$9.45
From 52W high
−69.79%
Volume
2.00
Market cap
$1.04B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
22.1
MomentumView details →
1D Return
+0.67%
YTD Return
−60.87%
SummaryUpdated Jun 1, 2026
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands. The company went public in February 2021 and focuses on developing innovative treatments for metabolic diseases, particularly cardiovascular conditions related to cholesterol management. NewAmsterdam's primary focus is advancing its lead drug candidate through clinical trials to address unmet medical needs in cholesterol treatment and cardiovascular disease prevention.
Similar companies
Latest newsMore news →
NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence of preclinical Alzheimer's disease.21d agoThe European Commission approved NewAmsterdam Pharma and Menarini Group's Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe.29d ago